AbbVie Inc. $ABBV Stock Sold by Vest Financial LLC

Vest Financial LLC lowered its position in AbbVie Inc. (NYSE:ABBV) by 16.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 224,688 shares of the company’s stock after selling 43,631 shares during the quarter. Vest Financial LLC’s holdings in AbbVie were worth $58,776,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ABBV. Ranch Capital Advisors Inc. increased its holdings in AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after buying an additional 4,017 shares during the last quarter. Capital Advisors Inc. OK raised its stake in AbbVie by 11.2% in the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after buying an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new stake in AbbVie during the 2nd quarter worth about $23,557,000. Wedge Capital Management L L P NC lifted its holdings in AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, State Street Corp boosted its position in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ABBV shares. Guggenheim reiterated a “buy” rating and issued a $288.00 price objective on shares of AbbVie in a report on Friday, October 9th. Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Oppenheimer boosted their target price on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Canaccord Genuity Group boosted their target price on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Scotiabank upped their price target on AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $278.07.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

AbbVie Price Performance

NYSE ABBV opened at $284.59 on Friday. The firm’s fifty day moving average price is $265.60 and its 200 day moving average price is $241.46. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40. The company has a market capitalization of $502.80 billion, a price-to-earnings ratio of 80.39, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the company earned $2.97 earnings per share. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s payout ratio is 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.